Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H44N2O10.2ClH |
| Molecular Weight | 665.6 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN(C)CCN(C)CCCOC(=O)C2=CC(OC)=C(OC)C(OC)=C2
InChI
InChIKey=GIOKUMNZQFCEPI-UHFFFAOYSA-N
InChI=1S/C30H44N2O10.2ClH/c1-31(11-9-15-41-29(33)21-17-23(35-3)27(39-7)24(18-21)36-4)13-14-32(2)12-10-16-42-30(34)22-19-25(37-5)28(40-8)26(20-22)38-6;;/h17-20H,9-16H2,1-8H3;2*1H
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2096682 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2579237 |
1.4 µM [IC50] | ||
Target ID: GO:0046085 |
0.7 µM [IC50] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Release of adenosine and ATP during ischemia and epilepsy. | 2009-09 |
|
| Short-term and long-term cognitive function and cerebral perfusion in off-pump and on-pump coronary artery bypass patients. | 2006-01 |
|
| [Use of instenon in complex treatment of patients with optic nerve atrophy caused by craniocerebral trauma]. | 2004-01-08 |
|
| [Pharmacological prevention of cerebrovascular complications in cardiac patients after coronary artery bypass surgery]. | 2003 |
|
| [The use of instenon in children with minimal brain dysfunction]. | 2002 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB35797
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | |||
|
200-054-7
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | |||
|
439431
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000128565
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | |||
|
5776
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | |||
|
m6011
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | Merck Index | ||
|
50-62-4
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | |||
|
P60CS4TIHV
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY | |||
|
DTXSID90964485
Created by
admin on Mon Mar 31 20:52:11 GMT 2025 , Edited by admin on Mon Mar 31 20:52:11 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD